LENSAR Q1 revenue $10.6M (+28% YoY); net loss narrows to $2.2M

LENSAR, Inc.

2024-Q1 EPS reported -$0.19 revenue$10,588,000

Total revenue $10.6M for Q1 2024, up 28% YoY; net loss $2.2M ($0.19 per share) vs $4.3M ($0.40) loss in Q1 2023.
Worldwide procedure volume increased 25% to 39,486; U.S. procedure volume up 23%. Installed base of ALLY systems reached 65.
U.S. procedure share grew 1.5% sequentially from Q4 2023, the highest single-quarter gain since ALLY launch; total share up 4.3% since launch.
Adjusted EBITDA loss improved to $1.3M from $1.8M; SG&A flat at $6.8M, R&D down 12% to $1.4M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LENSAR, Inc. reported quarter ended March 31, 2024 results: revenue $10.6 million, net income $2.2 million, EPS ($0.19) per common share.

Period: quarter ended March 31, 2024
Revenue: $10.6 million
Net income: $2.2 million
EPS: ($0.19) per common share
Result: reported results

Exact text from the filing

and staff as well as better surgical outcomes for patients, allowed us to deliver continued 20%+ revenue growth in the first quarter of 2024. Total revenue for the quarter was $10.6 million, up 28% over the first quarter of 2023. Moreover, procedure volume grew by 23% in the U.S., our largest market and the only country where ALLY is currently marketed,” said Nick

View on SEC.gov

Browse all earnings releases →

LENSAR, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056284

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.